Head-to-head · Cost-Efficiency Index
NexLife vs Curve
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NexLife
Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate.
Visit NexLifeCurve
Cost-first shoppers who want legitScript-certified compounded GLP-1 at flat per-dose pricing.
Visit CurveThe verdict
NexLife and Curve tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with NexLife (ranked #185, a hair above #192) — Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate. But Curve is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NexLife.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NexLife | Curve |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | $165/mo (all doses, compounded) | $175/mo (compounded) |
| Tirzepatide / mo | $215/mo (all doses, compounded) | $225/mo (compounded) |
| Semaglutide / yr (modeled) | $1,980 | $2,100 |
| Tirzepatide / yr (modeled) | $2,580 | $2,700 |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #185 | #192 |
NexLife
63/100Where the value is
- Flat pricing confirmed at every dose for both drugs — no per-mg escalation during titration, unlike most compounded competitors in this batch
- LegitScript certified with a named medical director (Adam Kennah, M.D.)
- States every batch undergoes independent third-party testing for potency, sterility, pH, and endotoxin levels
The tradeoffs
- The commonly advertised '$186/mo' tirzepatide headline requires a 12-month commitment; the true no-commitment month-to-month price is $215/mo — about 16% more
- No individual compounding pharmacy is named, only 'LegitScript-certified, NABP-accredited' pharmacies generically
Regulatory note: the FDA issued a warning letter to Nexlife Inc. dba Nexlife in June 2026. We still list and link to NexLife; you should know the letter is on the public record before you decide.
Curve
63/100Where the value is
- Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
- LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
- Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
The tradeoffs
- Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
- The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.